ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1676

Changing Patients’ Mindsets About Non-Severe Side Effects of Methotrexate: A Randomized Controlled Trial
Abstract Number: 1677

Safety and Efficacy of FNS007, a Non-T Cell Receptor Contacting Peptide, for Patients with Active Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial
Abstract Number: 1678

Efficacy, Safety, Pharmacokinetics of Anti-CD40 Antibody Abiprubart in Patients with Rheumatoid Arthritis: A Phase 2, Randomized, Placebo-Controlled 12-week-treatment Proof-of-Concept Study
Abstract Number: 1679

Differential Pharmacodynamic Changes of Circulated Immune Subsets After Treatment with Abatacept or Adalimumab in Patients with ACPA+ Early RA in the AMPLIFIED Study
Abstract Number: 1680

Reporting Quality of Non-inferiority and Equivalence Rheumatoid Arthritis Randomized Clinical Trials: A Systematic Review
Abstract Number: 1681

Safe Switching from Originator Tocilizumab to MSB11456 Tocilizumab Biosimilar in Subjects with Moderate-to-Severe Rheumatoid Arthritis: Efficacy, Safety and Immunogenicity Data Following Treatment Transition in a Pivotal, Randomized, Double-blind, Phase III Study
Abstract Number: 1682

Early Development of Ocadusertib, a Selective Receptor-Interacting Serine/Threonine-Protein Kinase 1 Inhibitor
Abstract Number: 1683

68Ga-FAPI PET/CT Imaging for Assessing Renal Tubulointerstitial Fibrosis in Lupus Nephritis
Abstract Number: 1684

Autoantibodies to Transcription Factor a Mitochondria Are Associated with Damage Accrual, Malignancy Risk and Mortality in SLE
Abstract Number: 1685

The Renal Activity Index for Lupus (RAIL) Identifies Active Renal Disease in SLE Patients and Its Longitudinal Score Associates with Achievement of Renal Responses in Lupus Nephritis
Abstract Number: 1686

Urine Proteomics in Class II Lupus Nephritis Reveals Immune Activation and Pro-Fibrotic Signatures
Abstract Number: 1687

IgG and IgA anti-LIN28A Outperform Anti-dsDNA and anti-Sm in Distinguishing SLE from Health and Other Autoimmune Diseases
Abstract Number: 1688

Discovery and Validation of a New Classification of ANA-RMDs That Better Predict Long Term Outcomes Compared to Legacy Diagnoses
Abstract Number: 1689

Pulmonary Function Test Reference Equations May Drive Inequitable Classification of Restrictive Lung Disease Severity in Systemic Sclerosis
Abstract Number: 1690

FAPI-PET/CT as a Predictor of Accelerated Lung Function Deterioration in Systemic Sclerosis Related Interstitial Lung Disease (ILD): Preliminary-interim Analysis from a Confirmatory Risk Factor Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].